VEGFA and neoplasm: Meanwhile, anti-angiogenic agents inhibit the VEGF pathway, reducing tumor blood supply, and potentially normalizing the tumor vasculature, which can improve immune cell infiltration and enhance the efficacy of immune checkpoint inhibitors (5).